Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Management of Peripheral Edema in Patients with Heart Failure

Assessment and Diagnosis

  • The American Heart Association recommends that patients with heart failure and hypertension should have their blood pressure controlled to a target of <140/90 mmHg, as uncontrolled blood pressure can worsen heart failure symptoms 1, 2
  • Patients with heart failure often present with lower extremity edema, hypertension, and are typically on medications such as Entresto and metoprolol, which are appropriate for heart failure management 2
  • The American College of Cardiology recommends the use of thiazide or thiazide-type diuretics for blood pressure control and to reverse volume overload and associated symptoms in patients with heart failure 2, 3
  • Diuretics should be used together with an ACE inhibitor/ARB and a beta-blocker, as this combination has been shown to improve outcomes in patients with heart failure 2
  • Thiazide diuretics are preferred in hypertensive heart failure patients with mild fluid retention because they confer more persistent antihypertensive effects than loop diuretics 3, 4

Monitoring and Follow-up

  • The American Heart Association recommends follow-up within 1-2 weeks to assess response to diuretic therapy by checking for improvement in edema, weight loss, and blood pressure control 5

When to Consider Cardiology Referral

  • The European Society of Cardiology recommends cardiology referral if the patient does not respond adequately to the addition of a thiazide diuretic, or if there are signs or symptoms suggestive of worsening heart failure 1, 2, 6, 5
  • Cardiology referral is also recommended if there is significant worsening of renal function or development of severe hyponatremia or hyperkalemia with diuretic therapy 5

Alternative Diuretic Options

  • The American College of Cardiology recommends considering the addition of an aldosterone receptor antagonist if there is evidence of heart failure with reduced ejection fraction, or switching to a loop diuretic if there is severe heart failure or severe renal impairment 2, 7

REFERENCES